Longstanding claims that one of the reasons for high drug prices in the US is the actions of pharmacy benefit management ... investigated by the Federal Trade Commission (FTC).

Agency commissioners voted unanimously on Tuesday to publish the report, which makes a similar attack on the drug middlemen as the agency’s first report, but draws on more data.

FTC: ‘Big 3’ Pharmacy Benefit Managers Engaged in Price Gouging, PBMs, UnitedHealth OptumRx, CVS Caremark Rx, Express Scripts ...

The Federal Trade Commission has released its second report digging into how the business practices of pharmacy benefit managers ... The Pharmaceutical Care Management Association, the largest ...

I'm an antitrust expert and former FTC ... benefits of PBM activities may be quite substantial. In a July 2022 National Bureau of Economic Research working paper, The Value of Pharmacy Benefits ...

At a public meeting held on January 15, 2025, the Federal Trade Commission (FTC) summarized the Second Interim Staff Report ...

The largest pharmacy-benefit managers hiked ... vice president of the Pharmaceutical Care Management Association, a trade association representing PBMs. The FTC analyzed data submitted by the ...

The industry says it keeps down the cost of prescription drugs, but critics say it's profiting at the expense of patients.

were down around 1% after the Federal Trade Commission (FTC) accused their pharmacy benefit manager units of imposing significant price markups on specialty generic drugs, according to a new ...

For a moment, it looked like Congress would actually enact reforms of controversial pharmacy benefit managers ... to curb PBMs’ practices. The Federal Trade Commission in September sued the ...